Is Viridian Therapeutics Stock a Good Investment?
Viridian Therapeutics Investment Advice | VRDN |
- Examine Viridian Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Viridian Therapeutics' leadership team and their track record. Good management can help Viridian Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Viridian Therapeutics' business and its evolving consumer preferences.
- Compare Viridian Therapeutics' performance and market position to its competitors. Analyze how Viridian Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Viridian Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Viridian Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Viridian Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Viridian Therapeutics is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Viridian Therapeutics Stock
Researching Viridian Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 100.0% of the company outstanding shares are owned by institutional investors. The book value of Viridian Therapeutics was at this time reported as 5.96. The company recorded a loss per share of 3.07. Viridian Therapeutics last dividend was issued on the 13th of November 2020. The entity had 1:15 split on the 13th of November 2020.
To determine if Viridian Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Viridian Therapeutics' research are outlined below:
| Viridian Therapeutics generated a negative expected return over the last 90 days | |
| Viridian Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 302 K. Net Loss for the year was (269.95 M) with loss before overhead, payroll, taxes, and interest of (237.95 M). | |
| Viridian Therapeutics currently holds about 161.21 M in cash with (232.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.66. | |
| Viridian Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: Commit To Buy Viridian Therapeutics At 12.50, Earn 13.2 percent Annualized Using Options - Nasdaq |
Viridian Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Viridian Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Viridian Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Viridian Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Viridian Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Viridian Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-08 | 2024-06-30 | -0.89 | -1.02 | -0.13 | 14 | ||
2022-11-14 | 2022-09-30 | -1.02 | -0.86 | 0.16 | 15 | ||
2022-08-15 | 2022-06-30 | -0.9 | -1.06 | -0.16 | 17 | ||
2023-11-13 | 2023-09-30 | -1.27 | -1.09 | 0.18 | 14 | ||
2021-11-04 | 2021-09-30 | -1.47 | -1.25 | 0.22 | 14 | ||
2025-02-25 | 2024-12-31 | -1.0442 | -0.81 | 0.2342 | 22 | ||
2024-05-08 | 2024-03-31 | -1.1 | -0.79 | 0.31 | 28 | ||
2024-02-27 | 2023-12-31 | -1 | -1.35 | -0.35 | 35 |
Viridian Therapeutics Target Price Consensus
Viridian target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Viridian Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 17 | Strong Buy |
Most Viridian analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Viridian stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Viridian Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationViridian Therapeutics Target Price Projection
Viridian Therapeutics' current and average target prices are 14.81 and 40.44, respectively. The current price of Viridian Therapeutics is the price at which Viridian Therapeutics is currently trading. On the other hand, Viridian Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Viridian Therapeutics Market Quote on 25th of March 2025
Target Price
Analyst Consensus On Viridian Therapeutics Target Price
Viridian Therapeutics Analyst Ratings
Viridian Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Viridian Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Viridian Therapeutics' financials, market performance, and future outlook by experienced professionals. Viridian Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Viridian Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Viridian Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Viridian Therapeutics backward and forwards among themselves. Viridian Therapeutics' institutional investor refers to the entity that pools money to purchase Viridian Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Novo A/s | 2024-12-31 | 2.2 M | Maverick Capital Ltd | 2024-12-31 | 2.1 M | Driehaus Capital Management Llc | 2024-12-31 | 1.9 M | Paradigm Biocapital Advisors Lp | 2024-12-31 | 1.8 M | Adage Capital Partners Gp Llc | 2024-12-31 | 1.7 M | Geode Capital Management, Llc | 2024-12-31 | 1.7 M | Perceptive Advisors Llc | 2024-12-31 | 1.5 M | Loomis, Sayles & Company Lp | 2024-12-31 | 1.4 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 1.3 M | Fmr Inc | 2024-12-31 | 11.9 M | Blackrock Inc | 2024-12-31 | 5.8 M |
Viridian Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.26 B.Market Cap |
|
Viridian Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.36) | (0.38) | |
| Return On Capital Employed | (0.43) | (0.41) | |
| Return On Assets | (0.36) | (0.38) | |
| Return On Equity | (0.40) | (0.38) |
Determining Viridian Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Viridian Therapeutics is a good buy. For example, gross profit margin measures Viridian Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Viridian Therapeutics' profitability and make more informed investment decisions.
Evaluate Viridian Therapeutics' management efficiency
Viridian Therapeutics has return on total asset (ROA) of (0.3032) % which means that it has lost $0.3032 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4848) %, meaning that it created substantial loss on money invested by shareholders. Viridian Therapeutics' management efficiency ratios could be used to measure how well Viridian Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of March 2025, Return On Tangible Assets is likely to drop to -0.38. In addition to that, Return On Capital Employed is likely to grow to -0.41. At this time, Viridian Therapeutics' Total Assets are very stable compared to the past year. As of the 25th of March 2025, Non Currrent Assets Other is likely to grow to about 972.3 K, while Non Current Assets Total are likely to drop about 2.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.89 | 6.11 | |
| Tangible Book Value Per Share | 9.89 | 6.11 | |
| Enterprise Value Over EBITDA | (4.59) | (4.82) | |
| Price Book Value Ratio | 1.94 | 3.81 | |
| Enterprise Value Multiple | (4.59) | (4.82) | |
| Price Fair Value | 1.94 | 3.81 | |
| Enterprise Value | 1.2 B | 1.3 B |
Management at Viridian Therapeutics focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Beta 1.088 |
Basic technical analysis of Viridian Stock
As of the 25th of March, Viridian Therapeutics has the Variance of 10.59, risk adjusted performance of (0.12), and Coefficient Of Variation of (725.89). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Viridian Therapeutics, as well as the relationship between them.Viridian Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Viridian Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Viridian Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Viridian Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Viridian Therapeutics' Outstanding Corporate Bonds
Viridian Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Viridian Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Viridian bonds can be classified according to their maturity, which is the date when Viridian Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Viridian Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Viridian Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.42) | |||
| Mean Deviation | 2.61 | |||
| Coefficient Of Variation | (725.89) | |||
| Standard Deviation | 3.25 | |||
| Variance | 10.59 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.42) | |||
| Total Risk Alpha | (0.33) | |||
| Treynor Ratio | (0.43) | |||
| Maximum Drawdown | 13.48 | |||
| Value At Risk | (5.61) | |||
| Potential Upside | 4.19 | |||
| Skewness | (0.37) | |||
| Kurtosis | 0.0326 |
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.42) | |||
| Mean Deviation | 2.61 | |||
| Coefficient Of Variation | (725.89) | |||
| Standard Deviation | 3.25 | |||
| Variance | 10.59 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.42) | |||
| Total Risk Alpha | (0.33) | |||
| Treynor Ratio | (0.43) | |||
| Maximum Drawdown | 13.48 | |||
| Value At Risk | (5.61) | |||
| Potential Upside | 4.19 | |||
| Skewness | (0.37) | |||
| Kurtosis | 0.0326 |
Consider Viridian Therapeutics' intraday indicators
Viridian Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Viridian Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 35211.68 | |||
| Daily Balance Of Power | (0.90) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 15.08 | |||
| Day Typical Price | 14.99 | |||
| Price Action Indicator | (0.59) | |||
| Period Momentum Indicator | (0.65) | |||
| Relative Strength Index | 42.45 |
Viridian Therapeutics Corporate Filings
F3 | 12th of March 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 10th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 3rd of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
Viridian Stock media impact
Far too much social signal, news, headlines, and media speculation about Viridian Therapeutics that are available to investors today. That information is available publicly through Viridian media outlets and privately through word of mouth or via Viridian internal channels. However, regardless of the origin, that massive amount of Viridian data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Viridian Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Viridian Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Viridian Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Viridian Therapeutics alpha.
Viridian Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Viridian Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Viridian Therapeutics Corporate Management
| Seth Harmon | Principal Accounting | Profile | |
| Anthony Casicano | Chief Officer | Profile | |
| Kristian MBA | Chief CFO | Profile | |
| Melissa Manno | Chief Officer | Profile | |
| Anthony Casciano | Chief Officer | Profile | |
| Jennifer JD | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Viridian Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.